Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, fully integrated pharmaceutical company headquartered at Mumbai, India. It employs over 4100 people across its global operations and its shares are listed on India’s two large stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

The Company is a leader in India in the discovery of new molecules (Both NCES and Biologics) and is focused in the areas of inflammation [Asthma/COPD, etc] and metabolic disorders [Diabetes, Obesity, etc]. The Company has branded generic formulation interests in over 95 countries across the world including India, Europe, Brazil, Rest of Latin America (excluding Argentina), Russia/CIS, Africa and Asia. The formulations business spans several product segments such as Dermatology, Internal Medicine, Respiratory, Diabetes, Paediatrics, Gynaecology, ENT, and Oncology.

Glenmark Generics Limited (GGL), is a subsidiary of Glenmark Pharmaceuticals Limited (GPL) that aims to be a global integrated generic and API leader. GGL has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries. GGL has a strong base in Formulations development with teams operating out of laboratories in India and Latin America. The Company has a state-of-the-art manufacturing plant at Goa, India that is approved by US FDA, TPD (Canada), MHRA, UK and many other overseas regulatory authorities. GGL also markets over 45 APIs to more than 80 countries across the world and had over 30 USDMFs filed and/or approved along with several DMFs in Canada.

For more information click –
www.glenmark-generics.com

Global Footprint

Glenmark has built a visible and growing branded generic formulation presence across all its markets in Latin America, Europe, Asia, Africa and CIS countries. A number of its products have emerged as brand leaders in India and some of these markets. Glenmark has made acquisitions in Brazil, South Africa and Czech Republic and is currently looking to acquire companies in Europe.

Research lies at the heart of Glenmark's business as affirmed in its vision.

Glenmark is among the few Indian pharmaceutical players targeting new drug discovery research. Today, Glenmark has a pipeline of 13 molecules; six of which are in clinical development and the other seven are at various stages of preclinical development and discovery. The Company has been able to build an admirable pipeline of molecules within a short span in the targeted areas of inflammation and metabolic disorders.

Glenmark has a strong NCE pipeline with three molecules in Phase II
The Company’s new drug discovery research is carried out at its state-of-the-art research centre at Mahape, in Navi Mumbai.

Glenmark’s biopharmaceutical research is carried out in its research centre in Switzerland. This facility was established with an aim to diversify into research activities to cover biologics and now has a team of more than 50 scientists with Biologics Research experience, from Switzerland and Europe.
Glenmark also recently acquired two New Biological Entities (NBE’s) from Chromos Molecular Systems Inc. of British Columbia, Canada. These two NBE’s are monoclonal therapeutic antibodies for the treatment of Multiple Sclerosis and Acute Stroke.

Glenmark Pharmaceuticals Ltd. signed a landmark USD 190 million deal with Forest Laboratories in 2004 for developing and marketing Oglemilast, Glenmark’s lead molecule for Asthma/ COPD, for the North American region. In February 2008, Glenmark further received a milestone of USD 15 Million from Forest Labs. Glenmark and Forest Labs are working together closely to initiate additional studies for further long term development of Oglemilast, including a Phase II study in Asthma. The Company signed a similar deal with Teijin Pharma Ltd. for the Japanese territory for USD 53 million a few months later. Glenmark has retained the marketing rights for the rest of the world and is presently in discussions with potential partners in Europe.

With Eli Lily, Glenmark has signed a licensing deal for developing and marketing GRC 6211, Glenmark’s lead molecule for treatment of pain conditions, for North America, Europe and Japan which will generate revenues of close to USD 350 mn.